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Abstract
Background: Faecal incontinence (FI) is a substantial health problem with a prevalence of approximately 8% in
community-dwelling populations. Sacral neuromodulation (SNM) is considered the first-line surgical treatment
option in adults with FI in whom conservative therapies have failed. The clinical efficacy of SNM has never been
rigorously determined in a trial setting and the underlying mechanism of action remains unclear.
Methods/design: The design encompasses a multicentre, randomised, double-blind crossover trial and cohort follow-up
study. Ninety participants will be randomised to one of two groups (SNM/SHAM or SHAM/SNM) in an allocation ratio of 1:
1. The main inclusion criteria will be adults aged 18–75 years meeting Rome III and ICI definitions of FI, who have failed
non-surgical treatments to the UK standard, who have a minimum of eight FI episodes in a 4-week screening period, and
who are clinically suitable for SNM. The primary objective is to estimate the clinical efficacy of sub-sensory SNM vs. SHAM at
32 weeks based on the primary outcome of frequency of FI episodes using a 4-week paper diary, using mixed Poisson
regression analysis on the intention-to-treat principle. The study is powered (0.9) to detect a 30% reduction in frequency of
FI episodes between sub-sensory SNM and SHAM stimulation over a 32-week crossover period.
Secondary objectives include: measurement of established and new clinical outcomes after 1 year of therapy using new
(2017 published) optimised therapy (with standardised SNM-lead placement); validation of new electronic outcome
measures (events) and a device to record them, and identification of potential biological effects of SNM on underlying
anorectal afferent neuronal pathophysiology (hypothesis: SNM leads to increased frequency of perceived transient anal
sphincter relaxations; improved conscious sensation of defaecatory urge and cortical/subcortical changes in afferent
responses to anorectal electrical stimulation (main techniques: high-resolution anorectal manometry and
magnetoencephalography).
Discussion: This trial will determine clinical effect size for sub-sensory chronic electrical stimulation of the sacral innervation.
It will provide experimental evidence of modifiable afferent neurophysiology that may aid future patient selection as well as
a basic understanding of the pathophysiology of FI.
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Background
Faecal incontinence (FI) is defined as the recurrent involun-
tary loss of faecal material leading to a social or hygienic
problem (International Consultation on Incontinence: ICI)
[1] and not related to an acute diarrhoeal illness (Rome III).
While variations exist regarding prevalence due to differ-
ences in survey methods, screening questions, reference
timeframe, definition and population studied, few could
argue that FI is not a substantial health problem. Population
studies suggest a prevalence ranging from 3 to 15% in
community-dwelling women, 15% in community-dwelling
older people, 18–33% in hospitals, 38% in home health, and
up to 50–70% in nursing homes [2]. A clear relationship
with advancing age suggests that it will remain a problem
within the developing Western population demographic [2].
FI leads to substantive effects on quality of life in terms
of physical and emotional health; to stigmatisation and so-
cial isolation; and in older people, admission to residential
care. Societal costs incurred by lost work productivity and
absenteeism can be added to significant direct and indirect
medical costs attributable to drug and pad usage, to
specialist care, and particularly to nursing costs in older
patients. Such estimates probably under-reflect the full
impact of FI due to under-reporting [3]. It is estimated
that treatment of urinary and FI account for at least 2% of
the total UK healthcare budget [4].
Initial treatments of FI include pharmacological and
behavioural therapies, the latter generally incorporating
some form of biofeedback. While anecdotally these treat-
ments appear to improve continence in a significant num-
ber of patients there is little high-quality evidence to
support this [5]. Traditionally, surgical treatments
focussing on anal sphincter function are offered when
conservative measures fail. These can be classified into re-
constructive (sphincteroplasty), augmentation (bulking
agents) and neosphincter procedures (artificial sphincters,
graciloplasty). These procedures are invasive, irreversible,
and balance variable success rates against some risk of sig-
nificant morbidity. A stoma is the final option.
Neuromodulation is one of the fastest growing areas
of medicine: technologies now address diverse disease
areas including epilepsy, Parkinson’s disease and tremor,
chronic pain and deafness. The application of neuromo-
dulation to the problem of FI has significantly changed
the treatment paradigm for many patients over the past
20 years. Chronic stimulation of the sacral nerve roots
using an implanted electrode and generator – sacral
neuromodulation (SNM) is now considered the first-line
surgical treatment option for the majority of adults with
FI in whom non-operative therapies have failed to allevi-
ate symptoms (NICE 2007 [4]) especially as it is the least
invasive procedure. However, despite having regulatory
approval from the NICE and the U.S. Food and Drug
Administration (FDA), SNM remains an expensive inter-
vention with some limitations in terms of a high-quality
evidence base for either mechanism of action or efficacy.
Evidence of SNM efficacy
Numerous observational studies show that SNM leads
to substantial health gain for adults with FI with low
levels of operative morbidity compared to alternative
surgical strategies [6]. Reduced FI episodes correlate
with objective QoL improvements [7] and SNM has
been shown to be cost-effective with an ICER of £25,070
per quality-adjusted lif e year (QALY) lying within the
threshold recommended by NICE as an effective use of
NHS resources [7]. This systematic review, however, also
highlighted the generally poor methodological quality of
included studies which were almost universally
single-centre retrospective or prospective clinical case
series with unblinded observers and failure to report
outcomes on an intention-to-treat (ITT) basis. The latter
point is especially important since significant attrition
bias undermines nearly all studies even including the
higher-quality pivotal trial for FDA approval (a prospect-
ive multicentre US case series of 120 patients [8, 9]).
Two independent publications from Europe that have
reported large patient series using the ITT principle
have shown less encouraging results (circa 45%
long-term success) [10, 11].
Available randomised trial data for SNM in FI have re-
cently been systematically reviewed [12]. A total of six
included studies comprised four randomised crossover
designs and two parallel-group randomised controlled
trials (RCTs). One crossover included only two patients
[13]; a further study published only in abstract form re-
ported mainly mechanistic outcomes in only seven pa-
tients [14]. The remaining two crossover studies
included the widely cited study by Leroi et al. [15],
which enrolled 34 patients pre-selected on the basis of a
successful prior SNM implantation. Only 27 participated
in the crossover and only 24 completed the study (10
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excluded patients included four explantations due to
AEs and others due to lack of efficacy or protocol viola-
tions). Although the majority (18 / 24) of analysed pa-
tients preferred ‘ON’ vs. ‘OFF’ at the end of study, the
study failed to show a clinically meaningful reduction of
symptoms between ON and OFF periods; e.g. difference
in median FI episodes per week of only one episode.
This was suggested to result in part from a short wash-
out period (1 week) and a carry-over effect. A second
published crossover study [16] employed an identical
trial design but with smaller numbers of patients, rando-
mising only 16 of 31 preselected implanted patients and
thence only for two 3-week crossover periods. In con-
trast to the earlier study, significant decreases in FI epi-
sodes and summative symptom scores were observed in
the ON vs. OFF periods despite having no washout. In
an unblinded RCT by Tjandra et al. [17] 53 participants
with severe faecal incontinence in the SNM group expe-
rienced fewer episodes of faecal incontinence compared
to the control group which received optimal medical
therapy (mean − 5.20, 95% CI − 9.15 to − 1.25 at
3 months; mean − 6.30, 95% CI − 10.34 to − 2.26 at
12 months). Finally, an observer-blinded RCT of SNM
vs. a less invasive form of neuromodulation: percutan-
eous tibial nerve stimulation (PTNS) [18] demonstrated
a within-group effect size that was greater for SNM than
PTNS. While pilot in design and with small numbers
(n = 40 total), this effect was modest compared to most
observational case series.
Evidence of SNM mechanism
Traditional understanding of the pathophysiology and
surgical management of FI held that the sphincter ‘bar-
rier’ had primacy. It is now clear that while sphincter
disruption is still relevant to the development of FI in
many patients; e.g. obstetric injuries, it is only one factor
in complex defaecatory dysfunction that involves alter-
ation in unconscious anorectal and pelvic reflexes and
conscious modulation by the central nervous system
(CNS). SNM was developed for FI with the view that it
would augment defective sphincteric function [19]. It is
now well appreciated that patients with FI resulting from
pathophysiology other than primary sphincter dysfunc-
tion also benefit from treatment [20]. The importance of
sensory dysfunction on both urinary and bowel control
is being increasingly appreciated and there is strong
evolving evidence (including our own pilot data in
humans and experimental animals) that the mechanism
of action of SNM results primarily from modulation of
afferent nerve activity.
Pulling the above evidence together it is clear that the
clinical efficacy of SNM has never been rigorously deter-
mined in a trial setting. There is, therefore, a need for a
well-designed study of SNM that seeks to determine
definitive proof of clinical effect size and which notably
improves on the small number of existing randomised
studies and observational data. Such a study has the op-
portunity to embed a hypothesis-led mechanistic study.
Methods/design
Overall study aim
To determine clinical efficacy of sub-sensory, chronic,
low-voltage, electrical, sacral nerve-root stimulation
(SNM), using a commercially-available implantable




1. To determine whether chronic, sub-sensory SNM
leads to a minimum clinically-relevant reduction in
frequency of total FI episodes compared to SHAM
stimulation
 Hypothesis: SNM reduces frequency of total FI
episodes by a mean of 30% compared to SHAM
stimulation in the third month of chronic
stimulation
2. To determine the effect size of sub-sensory SNM
on a range of clinical outcomes compared to SHAM
stimulation
 Hypothesis: sub-sensory SNM leads to significant
and clinically-beneficial changes in a range of
established and novel innovative outcome mea-
sures in the third month of chronic stimulation
Secondary clinical objectives
1. To provide 12-month clinical outcome data for
SNM using optimised therapy (standardised lead
placement): cohort follow-up study
2. To validate new electronically recorded outcome
measures for future FI trials (and a new device to
record them)
3. To provide data on the kinetics of response and
carryover effects
4. To provide data on predictive value of baseline
characteristics and operative factors as covariates of
response (especially on optimised lead placement)
5. To increase general understanding of the basic
pathophysiology of FI in a well-characterised patient
cohort
Mechanistic objectives
1. To determine the effect of sub-sensory SNM on
anorectal sensorimotor reflex function
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 Hypotheses: (1) SNM but not SHAM increases
frequencies of fasting and fed perceived and
unperceived transient anal sphincter relaxations
(TASR) (based on prolonged high-resolution
anorectal manometry recordings) to levels observed
in healthy individuals; (2) SNM but not SHAM
increases conscious sensation of defaecatory urge
based on symptom reporting and objective
measures of anorectal sensory function
2. To determine the effect of SNM on anocortical
afferent function
 Hypothesis: SNM leads to brain plasticity (based
on magnetoencephalography (MEG)) in motor
and non-motor cortical and sub-cortical regions
Eligibility criteria
Inclusion criteria
 Adults aged 18–75 years
 Meet Rome III and ICI definitions of FI (recurrent
involuntary loss of faecal material that is a social or
hygienic problem and not a consequence of an acute
diarrhoeal illness)
 Failure of non-surgical treatments to meet the NICE
standard*
 Minimum severity criteria of eight FI episodes in a
4-week screening period (this is important to
exclude patients who might thence have zero FI
episodes during baseline evaluations)
 Ability to understand written and spoken English
or relevant language in European centres (due to
questionnaire validity)
 Ability and willingness to give informed consent
* Minimum NICE standard includes; diet, bowel habit
and toilet access being addressed. Medication, e.g. lo-
peramide, advice on incontinence products, pelvic-floor
muscle training, biofeedback and rectal irrigation should
be offered if appropriate [4].
All patients will have been determined as clinically
suitable for SNM based on clinical evaluation and subse-
quent multidisciplinary team discussion (as mandated by
NHS England specialist commissioning guidance) or
equivalent guidance in other participating EU countries.
Exclusion criteria
A standard list of exclusions (disease variants; surgical
fitness, specific contraindications to implantation) will
be used. Note that these are routine clinical exclusions
to the use of SNM rather than participation in the re-
search. For completion:
 Known communication between the anal and
vaginal tracts
 Prior diagnosis of congenital anorectal
malformations
 Previous rectal surgery (rectopexy / resection)
performed < 12 months ago (24 months for cancer)
 Present evidence of full-thickness rectal prolapse
 Prior diagnosis of chronic inflammatory bowel
diseases
 Symptoms of chronic constipation with over-flow
incontinence
 Structural abnormality of the pelvic floor leading to
clear evidence of obstructed defaecation based on
examination and/or imaging
 Symptoms of significant evacuatory dysfunction based
on Obstructive Defecation Syndrome Score ≥ 8
 Presence of active perianal sepsis (including
pilonidal sinus)
 Defunctioning loop or end stoma in situ
 Diagnosed with neurological diseases, such as
diabetic neuropathy, multiple sclerosis and
Parkinson’s disease
 Current or future need for MR imaging based on
clinical history
 Complete or partial spinal cord injury
 Bleeding disorders, e.g. haemophilia, warfarin
therapy
 Pregnancy or intention to become pregnant during
the study period
 Not fit for preferred method of anaesthesia
 Anatomical limitations that would prevent
successful placement of an electrode including
congenital abnormalities
 Psychiatric or physical inability to comply with the
study protocol (including e-diary assessments) at the
investigator’s discretion
 Is required to drive for long periods of time, e.g.
lorry drivers, taxi drivers and delivery drivers
Trial design
The overall design encompasses a randomised,
double-blind crossover trial and a follow-up cohort
study. The trial will be conducted in about 20 European
centres (UK and Germany) and in Ireland.
Randomised, double-blind crossover design overview
Ninety eligible participants will be randomly allocated to
two study arms after SNM implantation (see flow dia-
gram below (Fig. 1) and study scheme diagram (Fig. 2)).
Both arms have two intervention periods of 16 weeks’
duration (T0–T16 and T16–T32). Efficacy outcomes are
derived from assessments in the final 4 weeks of each
crossover period (T12–16 and T28–32), thus allowing
for almost 3 months’ intervention before outcome as-
sessments. A reprogramming session will be conducted
by the routine clinical care team at 6 weeks in both
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periods of both arms (T6, T22). Time points will have
an interval tolerance of ± 1 week for logistical
expedience.
Mechanism studies will be performed in a subgroup of
consecutively consenting patients equally from both
arms (to avoid risk of performance bias) until saturation
(n =minimum 20; aim 25 for both anorectal and anocor-
tical studies) in the final 2 weeks of the 4-week assess-
ment periods.
Cohort study: 12-month outcomes
After completing the crossover section of the study, pa-
tients will continue to be followed up for a further
26 weeks (estimated n = 75: allowing for dropouts). Dur-
ing this time they will have ‘open-label’ patient-decisive
stimulation (sub- or supra-sensory) as would be normal
for routine clinical practice. Further efficacy outcomes will
be recorded at T54–58. While it is accepted that these do
not represent true 1-year outcomes (16 weeks has been
SHAM treatment during the crossover), these will give an
indication of the short-term effectiveness of SNM using
the optimised lead placement and within the rigor of a
CTU-monitored randomised prospective study.
Study procedures
Recruitment and consent procedures
Patients will be consecutively assessed for broad eligibility
(using the inclusion/exclusion criteria checklist) from the
surgery waiting lists of participating centres and counselled
in detail about the study prior to any surgery; i.e. before test
stimulation (pre-enrolment). A minimum of 24 h will be
provided to enable consideration of patient information
sheets (PIS) and the study requirements. Consent for
screening and future enrolment will be conducted face to
face in a private setting with an appropriately trained and
delegated member of the clinical or research team. Patients
will consent to the study (T–18: see Fig. 1) up to 4 weeks
prior to surgery.
Randomisation procedures
Group 1 (45): SNM/SHAM
Group 2 (45): SHAM/SNM
Randomised allocation (1:1) will be performed at the
time of surgery using a computer-based programme de-
veloped by the PCTU and stratified by sex and centre
Fig. 1 Flow diagram
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with block sizes of 4. The inclusion of sex as a stratifica-
tion factor is justified by the potential differences in
pathophysiology in the small number of male patients
with significant FI [21]. Patients will be randomised
prior to surgery so they enter the study even if it is not
possible to implant the stimulator. If there is any
problem with the online randomisation system, random-
isation can be delayed up until the initial programming
giving a window of 2 weeks; alternatively, emergency
randomisation may be performed by an unblinded mem-
ber of the coordinating team.
Blinding procedures
Research investigators and participants will be blinded
to intervention status (SNM or SHAM). Patients will be
informed of the allocation ratio of 1:1 and that blinding
prevents them from knowing in which group they are
participating (and, therefore, their order of intervention
sequence). Patients will be issued with a patient pro-
grammer (InterStim iCon Patient Programmer Model
3037) with tamper-proof tape cut so as to obscure the
stimulator setting but not obscure the on-off icon
(which is in the top left-hand corner of the screen). This
enables the patient to switch off the stimulator in an
emergency; e.g. unwanted neurological AEs (the only
emergency that would require this) and to permit driv-
ing (manufacturer’s guidance recommends that the
stimulator should be turned off for driving). When the
patient has completed their car journey they will simply
reactivate the device which will return to the pre-set
level (SNM or SHAM). This is a pragmatic consider-
ation that is both necessary to complete the study (re-
cruitment would be impossible if patients could not
drive for the whole 32-week crossover period) and part
of ‘real-life’. There is published evidence that switching
the device off for part of the day (even for long periods)
Fig. 2 Study scheme diagram
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has no effect on efficacy over a chronic stimulation
period [22–24]. The settings on the device (to turn
stimulation settings up or down) will not be accessible
to the participants, having been disabled at the time of
programming, in addition to the external buttons being
covered with tamper-proof tape. The patient program-
mer power switch, neurostimulator synchronisation
switch and neurostimulator on/off switch will be access-
ible to the patient.
The Model 8840 Clinician programmer is able to ac-
cess log data of stimulation usage so there is potential to
check all data on ON-OFF cycling during the study
intervention periods if this is required to validate fidelity
of the intervention (a bit like used blister-packs to count
unused drugs in a drug trial). During the SHAM period
the neurostimulator will be active but not be providing
stimulation (current set to 0 V). Therefore, analysis of
neurostimulator activity in the SNM and SHAM phases
should be equivocal in percentage of neurostimulator
‘use’ and un-blinding one participant would not com-
promise blinding for the remainder. The digital pro-
gramming unit (N’Vision Clinician Programmer Model
8840) will not be supplied to the patient but can be used
post hoc to determine if the patient has changed settings
or switched stimulation on or off during the study (the
programmed settings will also have been recorded on a
case report form (CRF) by the unblinded clinical team
member). The patient will not be removed from the
study if the tamper-proof tape has been broken. This will
be recorded for statistical analysis.
A nominated member of the research team or normal
care clinician will have access to the programmer at the
relevant fixed time points for stimulator adjustment
(crossover and 6-week reprogramming). This person who
will not be blind to intervention status will not otherwise
be involved in the research protocol; e.g. outcomes assess-
ments, collection of CRFs, data management.
Planned interventions
Sacral neuromodulation (SNM) (Medtronic Interstim®)
The intervention is chronic low-voltage stimulation of
the third sacral root using surgical implantation of a
commercially available CE-marked active implantable
(class III) medical device (Medtronic Interstim®) used in
accord with the manufacturer’s instructions.
Patients meeting the mandated response using the
monopolar temporary wire or quadripolar tined lead
(lead choice and duration of testing based on local surgi-
cal practice) will undergo implantation of the permanent
InterStim system under general or local anaesthesia
(with sedation) by trained expert colorectal surgeons fol-
lowing the procedural steps developed by Siegel [25] and
now published as full guidance [26] (in brief:
fluoroscopic-aided percutaneous insertion of 3889 lead
using curved stylet and accepting position only when
three out of four electrodes provide low-voltage (< 3 V)
contraction of the anal sphincter and pelvic floor ± big
toe). The implantable pulse generator (3058; Medtronic)
will be placed as pre-marked in the ipsilateral buttock
only if electrode responses meet the Siegel criteria.
The device will be activated as per local policy. This
can be in the post-operative period the same day as
surgery or after a surgical stabilisation period of up to
2 weeks (this is routine clinical practice in some
centres).
General programming parameters will accord with a
written algorithm based on best clinical practice. Prior
to programming, an impedance check will be performed
and recorded to ensure integrity of the electrical system.
The clinical team will set the electrode configuration to
achieve sensory threshold defined as the stimulation
amplitude where the patient feels the first sensation of
stimulation in the anus or perineum (or vagina) at a
14-Hz frequency, pulse width 210 μsec (a perception of
anal sphincter stimulation is considered by most to be
optimal). To determine the amplitude necessary to elicit
an anal sensation, the amplitude will be increased by
0.1 V from zero until the sensory threshold is reached
[27]. The dominant electrode will be defined by initial
mono-polar testing of each electrode noting the site of
sensation and sensory threshold with each electrode
used. The optimal electrode configuration will then be
determined based on the programming algorithm. The
amplitude required to elicit the sensory threshold with
the optimal electrode configuration will be recorded.
The patient will continue with stimulation at sensory
threshold for 5 min, and the process then repeated to
identify the habituated sensory threshold. Sub-sensory
chronic stimulation will then be performed at the level
of the habituated sensory threshold [15] setting the de-
vice at this level. The maximum stimulation setting will
be set at the habituated sensory threshold to ensure that
an individual patient is unable to increase the amplitude
of stimulation to above the sensory threshold and, there-
fore, determine whether they are receiving active stimu-
lation or not.
At the 6-week time point after device activation, the pa-
tient will be re-assessed by the un-blinded research dele-
gate or clinician. Changes in electrode configuration will
be permitted if a patient is having sub-optimal efficacy or
significant unwanted effects of stimulation. Any change in
electrode configuration or site of sensation will be docu-
mented. The habituated sensory threshold will be
re-calculated and stimulation thence returned to this level.
SHAM stimulation
Device implantation and post-operative optimisation
proceeds as above. The habituated sensory threshold is
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recorded identically. However, the device is then
returned to 0 V and (device remains on but will provide
no stimulation). At the 6-week time point after device
implantation, the patient is re-assessed for sub-optimal
efficacy (anticipated in the majority if the fundamental
hypothesis is correct) by the un-blinded research dele-
gate or clinician. To maintain blinding, an identical pro-
cedure is followed as above; i.e. re-evaluation of sensory
threshold and electrode configurations but this is
followed by returning the stimulator to 0 V.
Procedures for mechanistic studies (subgroup of patients)
Because mechanistic studies involve quite burdensome
studies and because anocortical (MEG) studies can only
be performed at the Wellcome Trust Laboratory for
MEG studies, Aston Brain Centre by highly experienced
investigators (Furlong, Hamdy), two separate cohorts of
patients will be recruited and separately consented for
anorectal and anocortical studies. The numbers of pa-
tients for each will be defined by ability to recruit and
retain patients in these studies and are in part a function
of geographical location of recruitment; however, we will
aim to recruit 25 patients to the both anorectal and ano-
cortical studies (see ‘Sample size’ section).
Anorectal studies Patients in the London area (several
centres) will be identified as potential subjects and pro-
vided with the specific PIS. Interested patients will need
to make two visits to the GI Physiology Unit at Barts
Health NHS Trust. Patients will undergo quick (clinic-
ally routine) tests of anal and rectal sensory function.
The high resolution manometry catheter (Medical Meas-
urement Systems) is then inserted and a standard (clinic-
ally routine and internationally agreed) protocol [28] of
basic pressure measurements obtained. Thereafter, the
patient will undergo a prolonged recording (total 1.5 h)
of anorectal pressures at rest in a semi-recumbent pos-
ition in a private room before and after a test meal
(45 min each phase). During this time, they can watch
TV but will be instructed to press an event recorder for
any episodes of ‘urge’ or passage of flatus and complete
a sensation record. The catheter is then removed and
the study is finished.
Anocortical studies
Patients in the Midlands area (Sandwell and West Bir-
mingham NHS, University Hospital Birmingham, Heart
of England NHS and University of Leicester NHS
Trusts) will be identified as potential subjects and pro-
vided with the specific PIS. Interested patients will need
to make a total of three visits to the Aston Brain Centre.
Only patients known to be proceeding to implantation
will be invited for baseline evaluation and this can only
proceed after removal of the test electrode (due to
magnetic resonance imaging (MRI)) or in those in whom
there is good certainty that a tined lead evaluation will
progress to implantation. A baseline MEG will be acquired
according to the specific protocol developed and tested by
the applicants (see Fig. 3). At the same visit (but after the
MEG) they will have an MRI head scan. At the second
and third visits (SNM or SHAM in random sequence), the
patient will have further MEG acquisitions only.
Study visits
The study visits are shown in the Standard Protocol Items:
Recommendations for Interventional Trials (SPIRIT) Figure
(Fig. 4; Additional file 1).
Visit 0: Screening
Prior to visit 1 patients will be initially assessed for eligi-
bility against the inclusion and exclusion criteria check-
list. The multidisciplinary pelvic floor multidisciplinary
team (MDT) discussion needs to be reviewed prior to
visit 1. Eligible patients will be sent the REC-approved
invitation letter and PIS and invited to attend the visit 1
baseline visit. All patients screened will be added to the
screening log.
All study visits have a window of ± 1 week for logistical
purposes.
Screening and baseline visits
Visit 0: Screening
Prior to visit 1 patients will be initially assessed for eligibility
against the inclusion and exclusion criteria checklist. Pelvic
floor MDT discussion needs to be reviewed prior to visit 1.
Eligible patients will be sent the REC-approved invitation
letter and PIS and invited to attend the visit 1 baseline visit.
All patients screened will be added to the screening log.
Visit 1: Baseline
Eligibility against the inclusion/exclusion criteria will be
reviewed, then, after discussing the study and PIS, pa-
tients in agreement complete written informed consent.
This visit must take place no more than 18 weeks before
permanent implantation.
Once a patient has been consented they will have the
following assessments:
 Demographics, standardised medical/surgical history
taken including history of incontinence symptoms,
gynaecological history and pregnancy test (women
of childbearing potential)
 Clinical examination of perineum, anus and rectum
(if not documented previously within 6 months)
 Baseline outcome assessments: St Mark’s
continence score, Deferment time, Longo
Score, OAB-Q Short Form, International
Consultation on Incontinence Bowel (SF-ICIQ-B)
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questionnaire, Faecal Incontinence Quality of Life
(FI QoL) score and EQ-5D-5 L/Visual Analogue
Scale (VAS)
At this visit patients will also be given the 4-week
paper bowel diary (which will also record loperamide
usage and taught how to use the touch-screen electronic
device), which will be started from this visit.
A total of 4 weeks is provided to complete the diary. A
viscerosensory bowel diary will also be provided with in-
structions for completion over 5 days.
Surgical intervention visits
Visit 2a: Test stimulation
A 4-week window must be given between baseline and
test stimulation to allow for the completion of the baseline
bowel diary. Test stimulation will take place according to
routine care, this will require the patient to attend the
hospital as an outpatient, and no research data collection
is required. Test stimulation is, therefore, not considered a
study intervention and will be performed in accord with
local clinical practice. Based on previous data [6, 18], 15%
of patients will fail temporary SNM evaluation and will
not proceed to permanent implantation.
Visit 2b: Mechanistic study enrolment
Before permanent device implantation, those partici-
pants passing the test stimulation phase or those pa-
tients to have tined lead insertion with a high probability
of going through to permanent stimulation, will be se-
lected for and consented to the mechanistic study. All
patients must have completed the 4-week bowel diary.
Fig. 3 Magnetoencephalography (MEG) protocol for anocortical study
Fig. 4 Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) Figure
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Those selected for anocortical studies will then receive
the following investigations:
 MRI head
 MEG to electrical anal stimulation, anal squeeze,
sacral-root suprasensory stimulation, median nerve
stimulation
Visit 3a: Permanent device implantation (SNM implant)
Following test stimulation patients will be admitted as a
day case for permanent device implantation. Eligibility
for randomisation will be re-confirmed (assessment
baseline diary data). This visit must occur no later than
18 weeks after the baseline visit.
Patients are randomised prior to knife to skin to either
one of the two groups:
 Group 1 will the initially receive sacral
neuromodulation and
 Group 2 will initially receive SHAM stimulation
Sixteen-week SNM or SHAM periods will be counted
from the initial programming not from the day of
surgery.
Intraoperative data will be collected including:
 Lead position – radiological side and foramen level.
Number of electrodes in foramina
 Motor thresholds for each of the four electrodes on
the quadripolar lead
 Physiological motor (± sensory) response for the
chosen foramen for lead implantation
 Other intraoperative data: length of op, type of
anaesthesia (including use of any paralyzing agent),
blood loss, any other complications
Visit 3b: Initial programming (T0)
Post-operatively the implant will undergo baseline
checks using impedance measurements of the four elec-
trodes to ensure integrity of the electrical system. Pa-
tients will have their SNM programmed as per routine
care. This can be done in the post-operative recovery
period or up to 2 weeks post surgery. All further
follow-up visits will be counted from the initial pro-
gramming not from the day of surgery.
To reduce selection bias, no consenting patient with
an implant in situ will be excluded from participation;
i.e. regardless of the surgeon’s views on success or other-
wise of implantation. At each follow-up visit impedance
measurements will be repeated to ensure maintained in-
tegrity of the electrical system. If a closed or open circuit
is detected (suggesting possible neurostimulator or lead
malfunction) then this will be documented. If satisfac-
tory sensory response can be achieved using an
alternative electrode configuration then the patient will
be reprogrammed and can continue in the study. In the
absence of a satisfactory sensory response with an ab-
normal impedance measurement the patient will still be
followed up as per ITT and any changes to treatment
will be recorded in the deviation log.
At each visit any change in electrode configuration, sensory
threshold and location of maximum bodily sensation will be
recorded. The percentage of time the implant has been active
for will be recorded and the usage counters reset.
All programming will be performed using the Model
8840 N’Vision clinical programmer. The patient pro-
grammer can, therefore, be covered with tamper-proof
tape for the entire clinical trial and no access is required
to this device apart from to the power on/off button,
synchronisation button and implant on/off button.
Following initial programming:
 Group 1: the sub-sensory amplitude will be recorded
along with the electrode configuration used.
 Group 2: the sub-sensory amplitude will be recorded
along with the electrode configuration used before
returning the amplitude to 0 V
Any AEs will be collected at this visit and all subse-
quent face-to-face visits.
Crossover phases T0 to T32
Visit 4: 6-week reprogramming visit (T + 6)
The tamper-proof tape is left on the patient’s programmer,
programming is done via the clinician’s programmer.
 Group 1: patient assessed for sub-optimal efficacy or
unwanted effects of stimulation. In the presence of
sub-optimal efficacy or adverse effects the electrode
configuration can be changed as per reprogramming
algorithm. The sensory threshold is once again
recorded and device returned to the sub-sensory
setting
 Group 2: the sensory threshold is recorded and the
electrode configuration can be changed if the site of
stimulation appears to be sub-optimal (aim for anal
stimulation) before returning device to 0 V
Visit 5: Assessment (T + 12 to + 16)
All patients will start the 4-week paper bowel diary and
5-day viscerosensory diary. This can be sent by mail or
email, a face-to-face visit is not required.
The selected subgroup will have the first of the mech-
anistic follow-up studies completed (MEG or Anorectal).
Visit 6: Crossover visit (T + 16)
At crossover, the device is turned off for 20 min followed
by re-evaluation of the sensory threshold and best
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electrode configuration in the manner outlined above.
The intervention is then reversed for each arm.
Paper diary is completed and returned. Follow-up as-
sessment questionnaires (St Mark’s continence score,
Deferment time, OAB-Q Short Form, International Con-
sultation on Incontinence Bowel (SF-ICIQ-B) question-
naire, FI QoL score and EQ-5D-5 L/VAS). Patients will
also record their satisfaction on a Likert scale.
Visit 7: 6-week reprogramming visit (T + 22)
All patients will have a further follow-up 6 weeks after
crossover at T22.
Leaving the tamper-proof tape on the patient’s pro-
grammer, programming is performed using the clini-
cian’s programmer.
 Group 1: the sensory threshold is recorded and the
electrode configuration can be changed if the site of
stimulation appears to be sub-optimal (aim for anal
stimulation) before returning device to 0 V
 Group 2: patient assessed for sub-optimal efficacy or
unwanted effects of stimulation. In the presence of
sub-optimal efficacy or adverse effects the electrode
configuration can be changed as per reprogramming
algorithm. The sensory threshold is once again
recorded and the device returned to the sub-sensory
setting
Visit 8: Assessments (T + 28 to + 32)
All patients will start the 4-week paper bowel diary and
5-day viscerosensory diary. This can be sent by mail or
email, a face-to-face visit is not required.
The selected subgroup will have the second of the
mechanistic follow-up studies completed, (MEG or
Anorectal).
Open-label cohort follow-up T32–58
Visit 9: End of crossover (T + 32)
At 32 weeks (and after collection of final crossover study
data), patients will enter the follow-up phase with
patient-decisive stimulation (sub- or supra-sensory) as
would be normal for routine clinical practice. A member
of the clinical team will reprogramme the device accord-
ingly. Further programming and advice can be provided
as per routine care during the period 32–58 weeks. All
visits or contact with the clinical team during this time
will be recorded on the Note to File CRF.
The 4-week paper bowel diary and 5-day viscerosensory
diary will be completed and returned at this visit and the
set of follow-up assessment questionnaires (St Mark’s con-
tinence score, Deferment time, OAB-Q Short Form, Inter-
national Consultation on Incontinence Bowel (SF-ICIQ-B)
questionnaire, FI QoL score and the EuroQol Health
Outcome Measure (EQ-5D-5 L)/VAS). Patients will also
record their satisfaction on a Likert scale).
Visit 10: Final assessment (T + 54 to + 58)
Patients will be asked to complete a further paper bowel
diary and 5-day viscerosensory diary for the last 4 weeks
(T54–58). During the final visit both the e-diary and
paper diaries will be collected. Patients will undergo final
reprogramming and complete the outcome question-
naires and Likert scale. Any AEs will be reviewed and re-
solved. Patients will then be discharged from the study
and continue with normal clinical care.
Concomitant care and interventions
It is inevitable that participants will seek recourse to lo-
peramide and other medications during the course of
the programme. Breakthrough loperamide usage is cap-
tured on the patient diary and St Mark’s continence
questionnaire (see ‘Outcomes’ section). Additional con-
comitant medication reporting is not required for assess-
ment of eligibility or safety monitoring; e.g.
contraindication with the intervention. Thus, concomi-
tant medications will not be recorded.
Discontinuation criteria (participants and study)
Clinical care will take priority. The intervention plan al-
lows the direct care team to remain autonomous in clin-
ical decisions and modify their approach accordingly. It
is unlikely that the intervention will need to be formally
discontinued. However, if the direct care team or the re-
search team at any point feel that the intervention is af-
fecting the patient’s recovery, outcome or prognosis then
it will be discontinued immediately. The events and cir-
cumstances will be recorded. If any safety concerns have
arisen, these will be reported according to research gov-
ernance framework guidelines.
Withdrawal criteria
Patients can withdraw at any point in the study. The
data collected from consent to the point of withdrawal
will be kept for the ITT analysis, as outlined in the
patient information and consent form.
Patients will be withdrawn from treatment but
follow-up data will be continued to be collected if they:
 Electively withdraw from treatment
 Are not fit for surgery
 Become pregnant or intend to become pregnant
 Are unable to participate due to an concurrent
severe illness
 Develop an acute psychological illness causing
concerns
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Patients will be withdrawn from both treatment and
follow-up if they:
 Choose to withdraw from treatment and follow-up
data collection
 Become lost to follow-up (after at least three attempts
at contact by research/clinical staff using at least two
different methods)
 Die or become severely incapacitated so follow-up
data collection is impossible
Criteria for early termination
If the DMEC, TSC, REC or sponsor determine it is within
the best interests of the participants or trial to terminate
the study, written notification will be given to the CI. This
may be due to, but not limited to; serious safety concerns,
success or failure of the primary outcome, serious
breaches, acts of fraud, critical findings or persistent
non-compliance that negatively affects patient safety or
data integrity. If the study is terminated participants will
be returned to the normal follow-up and routine care.
Outcomes
Primary clinical outcome
The reduction in FI events in SNM vs. SHAM phase of
crossover (16 and 32 weeks).
Frequency of FI episodes per unit time will be
patient-recorded using 4-week paper bowel diaries. While
the limitations of this method are well established [29], this
remains the ‘gold standard’ in FI [15, 18, 27, 30] (we will,
however, be recording for 4 weeks rather than only 2 as in
many previous studies). The measure of treatment effect is
the average number of FI events per 4-week period for pa-
tients undergoing SNM as compared with the average
number of events for patients undergoing SHAM simula-
tion. The study is powered to detect a ratio of 0.7. This is
not to be confused with the reduction in the actual number
of events post intervention for a given patient, where a 50%
reduction has frequently been employed, albeit subjectively,
to define ‘success’ for that patient [18, 30]. Rather, we use
number of events as a quantitative outcome, achieving
greater power than a dichotomous outcome of successful/
unsuccessful, and we power to detect a 30% reduction, on
average, in this outcome on ITT principles.
The paper diary will be completed prior to implant-
ation then at the end of each crossover phase and again
at the end of the cohort follow-up.
Secondary clinical outcomes
A variety of quality of life questionnaire and bowel diary
measures recorded at 16, 32 and 58 weeks:
1. E-event recorder including episodes of faecal
material, leakage of flatus, urgency without
incontinence, social and physical activity (Fig. 5)
2. Other bowel diary measures: urgency, urge and
passive faecal incontinence episodes, use of
loperamide and social functioning
3. Summative questionnaire assessments: St Mark’s
continence score [31]; OAB-Q SF score, FI QoL
score [32]; International Consultation on Incontin-
ence Bowel (SF-ICIQ-B) questionnaire [33]
4. Viscerosensory bowel diary recording quality, site
and intensity of defaecatory urge
5. Generic QOL: EQ-5D-5 L
6. Likert scale of patient’s global impression of
treatment success (scale 0–10) and patient
perception of group allocation (blinding success)
7. Electrode settings (including motor, first and
habituated sensory thresholds), programming,
and, if applicable reprogramming data
8. Adverse events and morbidity
Mechanistic outcomes
Anorectal sensorimotor function
1. Frequency of perceived and unperceived TASRs per
unit time (pre- and post-prandial)
2. Anal sensory electrical threshold
3. Rectal volumetric thresholds (minimum, urge,
maximum tolerated) to balloon distension
Anocortical function
Magnetoencephalography (MEG): recordings will be ac-
quired in response to anal electrical stimulation at 75%
pain threshold, voluntary anal squeeze, and to acute
supra-sensory sacral-root stimulation. A synchronous
anal electromyogram (EMG) will also be recorded to aid
interpretation and a control area utilised (median nerve).
Whole cortical data will be obtained using standard
methods on an Elekta Triux 306 channel system uti-
lising noise cancellation methods to eliminate implant
and stimulator artefacts. A beam-former analysis
methodology will be employed to evaluate both
evoked and induced changes in brain activity associ-
ated with SNM and anal stimulation. Brain sources
will be constructed using individual co-registered
T1-weighted MRI brain volumes. The outcome of this
process will be a measure of the changes in brain
oscillatory power and/or frequency changes computed
from brain structures where maximum changes asso-
ciated with anal stimulation are observed. These
changes will be depicted in statistical brain volumetric
images.
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Statistical considerations
Sample size
The sample size is based on the primary outcome; i.e.
faecal incontinence episodes per unit time as recorded
using the 4-week bowel diary at the end of each 16-week
crossover phase.
We assume that when the device is inactive, the aver-
age number of events in 4 weeks for a typical participant
is 28. The number of events per month for that individ-
ual will have an over-dispersed Poisson distribution, with
95% range 7 to 112. But individuals will also vary, so the
average number of events in a month could vary from
14 in an individual at one extreme to 56 in an individual
at the other. This means that the correlation between
log(number of events) for the same individual in two
different months will be 0.2, and the standard deviation
of log(number of events) for each month will be 0.775
(this is consistent with results from two previous NIHR
trials in similar populations [18, 34], and with our clin-
ical experience). Thus, to detect a 30% reduction in FI
event rate with 90% power at the 5% significance level
with a crossover design requires 80 participants. Allow-
ing for 10% loss to follow-up a total of 90 participants
will be randomised. This sample size would also achieve
more than 90% power to detect a 50% reduction in FI
event rate using the data from the first period of the
crossover alone. This sample is also sufficient to detect
changes in mechanistic outcomes (90% power) based on
pilot data; i.e. using a one-sample test comparing loga-
rithm of anal electrical sensitivity post-SNM, the pro-
posed mechanistic sample size n = 25 will be sufficient
to detect a 30% reduction in sensory threshold with 95%
power at the 5% significance level, assuming the stand-
ard deviation of the change in log-sensitivity is 0.47
(consistent with a coefficient of variation of 0.5 for sensi-
tivity, as observed in pilot data, and a correlation of 0.5
between pre- and post-SNM assessments). The anocorti-
cal studies are mainly exploratory and sample size will
be based on success of recruitment. It is, however, envis-
aged that approximately 15 patients will complete all
three visits for MRI/MEG. Previous MEG studies have
drawn important conclusions with sample sizes of this
order.
Method of analysis
Efficacy: primary analysis from crossover study This
analysis will be completed by the statisticians at PCTU.
The analysis of the primary outcome will compare
SHAM and active therapy in both arms of the crossover
trial, at T12–T16 and T28–32, using mixed Poisson re-
gression analysis to adjust for a fixed effect of period
and a random effect of individual. To allow observed
numbers of events before and after activation in the
same individual to have an over-dispersed Poisson distri-
bution we will also include a random effect of time
within individual. We will analyse all non-missing data,
adjusting for the stratification variables (random effect
of centre and fixed effect of sex). This approach is
unbiased if missingness is related to observed outcome
data or stratification factors from the same participant (a
‘missing at random’ assumption): further sensitivity
analyses will explore this assumption if needed.
Secondary outcomes will be analysed in the same way
– using Poisson regression for outcomes that are counts,
and linear regression for other quantitative outcomes.
Exploratory analyses may also be performed using geo-
spatial data from the touch-screen devices to calculate,
e.g. number of outings from primary residence, as well
Fig. 5 Example photograph of touch-screen icons on
e-recording device
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as distance travelled and velocity (a surrogate for mode
of transport), and to produce numerical and graphical
summaries aggregated by trial arm.
Efficacy secondary analysis from cohort study As in
the primary efficacy analysis, mixed Poisson regression
will be used to compare the primary outcome at T52–58
with baseline in all randomised participants, adjusting
for a random effect of individual, and a random effect of
time within individual (over-dispersion).
Mechanism studies
Data from the subset of patients undergoing advanced
anorectal studies (n = 25 approx) will be collected during
each phase of the crossover. These data take the form of
counts, e.g. number of events, and continuous measures
such as pressure. Data will be analysed as for secondary
outcomes in the efficacy analysis.
Anocortical studies will be analysed by the Aston
Brain institute using existing bespoke computer analysis
packages (Graph (Elekta TM); Matlab TM and FieldTrip
TM and SPM8 TM). A beam-former analysis method-
ology [35] will be employed to evaluate both evoked and
induced changes in brain activity associated with SNM
and anal stimulation. Group analysis of this data will
allow determination of cortical reorganisational changes
associated with chronic SNM. This will be achieved by
the spatial normalisation of individual MRI volumes into
a grid based on the Montreal Neurologic Institute
(MNI) standard template. Statistical analysis will employ
a non-parametric cluster-based permutation test57.
Firstly, an uncorrected dependent-samples t test will be
performed on pre- and post-stimulus brain activity
across the entire brain volume. All voxels exceeding a
5% significance threshold will be grouped into clusters.
A null distribution will be obtained by randomising the
condition label (pre- or post-stimulus data) 1000 times
and calculating the largest cluster-level t value for each
permutation. This methodology has been shown to ad-
equately control for issues of multiple comparisons.
Confidentiality
Information related to participants will be kept confi-
dential and managed in accordance with the Data Pro-
tection Act 1998, The Data Protection Directive 95/46/
EC, NHS Caldecott Principles, The Research Govern-
ance Framework for Health and Social Care, ICH Good
Clinical Practice Guidelines (1996) and the conditions of
Research Ethics Committee Approval and current local
regulatory requirements.
All CRFs will be pseudonymised. The participant’s will
consent to their general practitioner (GP) and or refer-
ring clinician to be informed of their participation in the
study.
Access to data and archiving
The trial data will be made available to suitably qualified
members of the research team, study monitors and audi-
tors, the REC and regulatory authorities as far as re-
quired by law. When the research trial is complete, it is
a requirement of the Research Governance Framework
and Sponsor Policy that the records are kept for a mini-
mum period of 20 years (as per sponsor requirements).
Adverse events (AEs)
All AEs will be recorded on the CRF and in the medical
notes. Severity, causality (relationship to study procedures)
and assessment of seriousness will be at the discretion of
the medically qualified individual (e.g. principal investigator






 Worsening of, or de novo urinary incontinence
 Worsening faecal incontinence
 Unwanted/undesirable stimulation effects
 Numbness at neurotransmitter site
 Technical device issues including lead migration and
fracture
Expected serious adverse events (SAEs) are those re-
lated to routine use of SNM. These are:
 Infection of lead or implantable pulse generator (IPG)
necessitating removal or admission for intravenously
administered antibiotics
 Unwanted stimulation effects necessitating device
removal
 Lack/loss of efficacy necessitating device removal
 Revision of IPG placement due to discomfort or
displacement
 Revision or removal of IPG due to technical device
failure (including fractured lead or failure of
impedance check on all four leads)
 Unrelated hospitalisation; e.g. elective surgical
procedures or injury or acute medical problems
Notification and reporting of SAEs
SAEs that are considered to be ‘related’ and ‘unexpected’
are to be reported to the sponsor within 24 h of learning
of the event and to the Main REC within 15 days in line
with the required timeframe.
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Monitoring and auditing
The PCTU quality assurance manager will conduct a
study risk assessment in collaboration with the CI. Based
on the risk assessment, an appropriate study monitoring
and auditing plan will be produced according to PCTU
SOPs. This monitoring plan will be discussed and
authorised by the sponsor before implementation. Any
changes to the monitoring plan must be agreed by the
PCTU quality assurance manager and the sponsor. Au-
dits may be conducted by the sponsor or funder repre-
sentative. The study may be identified for audit via the
risk assessment process, investigator or department re-
quest, allegation of research misconduct or fraud or a
suspected breach of regulations or selected at random.
Trial committees
The project will be under the auspices of the chief inves-
tigator and the PCTU. The project will be overseen by a
Trial Steering Committee (TSC). The role of the TSC is
to provide overall supervision of the study on behalf of
the sponsor and funder to ensure the study is conducted
in accordance with the principles of Good Clinical Prac-
tice (GCP) and relevant regulations.
The responsibilities of the TSC will include: ensuring
that views of users and carers are taken into consider-
ation; advising on the trial protocol; advising on changes
in the protocol based on considerations of feasibility and
practicability; assist in resolving problems brought to it
by the Trial Management Group (TMG); monitor the
progress of the trial and adherence to protocol and mile-
stones; consider new information of relevance from
other sources; consider and act on the recommendations
of the Data Monitoring and Ethics Committee (DMEC),
sponsor and/or REC; review trial reports and papers for
publication.
A Trial Management Group (TMG) will meet monthly
initially during study set-up and then less frequently,
every 2 months. The TMG will be responsible for
day-to-day project delivery across participating centres,
and will report to the TSC.
A Data Monitoring and Ethics Committee (DMEC)
will be convened. The DMEC will meet at least 4 weeks
prior to the TSC to enable recommendations to be fed
forward. The DMEC will review unblinded comparative
data, monitor these data and make recommendations to
the TSC on whether there are any ethical or safety rea-
sons why the trial should not continue. The DMEC
membership will be in accordance with NIHR/MRC as
well as PCTU guidelines.
Risks / benefits
Efficacy study-related risks
The study poses no major risk to participants above the
standard risk of SNM therapy. SNM is an established
therapy whose main attraction is non-invasiveness and
safety compared to other surgical procedures. The short
period (3 months) without active therapy imposed by
the crossover design is not deemed ‘harmful’ for a
chronic and stable condition by the time that surgical
intervention is considered. The main procedural risks
are unwanted stimulation effects: muscle spasms, vaginal
pain, scrotal pain, leg pain and paraesthesia (common to
some degree but manageable usually by reprogram-
ming), infection (cited at 2%) and leading to device ero-
sion or removal. Other listed AEs (based on FDA: PMA
P080025) include: unwanted changes in bladder function
(urgency, retention); pain at neurostimulator and/or lead
site including skin irritation; and allergic or immune sys-
tem response to the implanted materials that could re-
sult in device rejections. Malfunction of the components
of the InterStim Therapy System including neurostimu-
lator programming error, lead migration/dislodgement,
lead fracture, erosion of the lead into the colon with per-
foration, neurostimulator battery depletion, extension
fracture, neurostimulator migration can also occur.
Taking the average natural background radiation in
the UK to be 2.3 mSv per annum, then an effective dose
of 1.6 mSv for this study is approximately equal to 8
months of natural background radiation exposure. X-ray
examination involves exposure to ionising radiation and
carries a risk of induction of excess cancers which may
not be expressed for many years after exposure. Using
the adult population lifetime risk coefficient of 5% per
Sievert gives a lifetime risk of cancer of approximately 1
in 12,500. The Public Health England Radiation Protec-
tion Division describes risks of this magnitude as very
low.
Some of the questionnaires contain personal questions
about bowel problems and the effect of these on quality
of life and psycho-behavioural functioning; however, all
have been used in studies of similar patients previously.
Mechanistic study related risks
For anocortical tests, the patient must be able to submit
for a pre-study registration MRI, have a plug anal elec-
trode inserted and sit in the MEG scanner for a total of
about 45 min; the patient must attend three times. These
tests are non-invasive and only confer mild discomfort
due to insertion of anal catheter. No ionising radiation is
employed by any tests.
For the anorectal tests, the main difference from rou-
tine clinical evaluation of anorectal function is the
addition of prolonged high-resolution anorectal manom-
etry. This test is not performed routinely and has a lon-
ger duration than standard studies (about 110 min); the
patient must attend twice. These tests are non-invasive
and only confer mild discomfort due to insertion of anal
catheter. No ionising radiation is employed by any tests.
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Study benefits
Participants will receive a high standard of surgery using
the latest technical optimisation and monitored care as
consequence of the protocol. All participants will receive
SNM therapy due to the crossover design. Participation
will add to the knowledge base for determining the
pathophysiology of disease and treating adults with FI.
Dissemination
Scientific findings will be subjected to international
reporting and peer review. We will direct this informa-
tion to the following groups: study participants and
carers who have been involved in the trial; charity links
and patient groups; NIHR collaboration.
Discussion
Double-blind efficacy study
A double-blind, randomised crossover design is appro-
priate to experimentally assess clinical effect size and to
study mechanism. The crossover will compare
sub-sensory chronic sacral-root stimulation against
SHAM stimulation with the well acknowledged advan-
tage of statistical efficiency. It is, however, also acknowl-
edged that such a study must improve on the previous
four attempts at crossover studies to provide useful effi-
cacy data. The proposed design will address the main
criticisms of previous studies:
1. Adequate intervention periods to adequately assess
response. We will have two 16-week periods (SNM
and SHAM) in comparison with previous studies
(maximum 1 month [15])
2. Adequate washout period and reduced risk of
carryover effects. While the duration of carry over
effects of SNM is unknown, the current study
design allows for almost 3 months’ washout before
outcomes are assessed, compared to a maximum in
previous studies of 1 week [15]. Clinical experience
suggests that this duration is adequate but we will,
nevertheless, continuously monitor the kinetics of
therapy and washout throughout the study using
the newly developed e-recording tools
3. Adequate statistical power, we propose a completed
crossover of 80 patients compared to previous
maximum of 24 [15]
4. Reduced selection bias. Although the crossover
design does not permit full adherence to an ITT
principle; i.e. from start of trial therapy with test
stimulation, we will randomise all newly implanted
patients rather than patients who have already been
selected on the basis of successful chronic therapy.
Selected patients will thus be naïve to chronic
stimulation and all consenting implanted patients
will be randomised
5. Reduced attrition bias. We will continue
assessments on all participants provided that the
patient has not withdrawn consent. Patients who
become unblinded to intervention would not,
however, contribute data to analysis
6. Improved patient blinding. We will use the
experience gained from the Durham-based NIHR
RfPB TiLTS-CC study to maintain blinding
7. Improved assessment methods (e.g. diaries are
collected for a longer period. As well as a paper
diary an electronic simple touch-screen device will
also be trialled)
We do, however, accept that the choice of design has
some limitations:
1. Although it is acknowledged that a small proportion
of patients prefer supra-sensory stimulation (about
10% in our clinical practice), especially in the short
term, for double-blinding it is clearly necessary to
mandate sub-sensory stimulation and we acknowledge
that this is in effect an experimental variant of the
therapy used in ‘real life’. We will, however, comply
with routine clinical practice by having a reprogramming
session at 6 weeks in each arm regardless of intervention
status; i.e. in the SHAM arm this will be a ‘pseudo-
reprogramming’ event. For the FI indication, a recent
randomised observer-blinded comparison showed
no difference in effects of supra- and sub-sensory
stimulation [27] building on a small study that
showed that therapeutic response threshold was
significantly lower than sensitivity threshold [36].
However, we acknowledge that some differences in
physiological results have been recorded for sub- and
supra-sensory stimulation in the patients with slow-
transit constipation [37] and this is acknowledged in
the study title
2. We acknowledge that it is difficult (and labour
intensive) to blind patients to SNM in crossover
designs, particularly for patients who receive the
intervention first and then have it switched to OFF.
This proved a problem in a recent study of irritable
bowel syndrome [38] in which 75% patients
correctly identified that the stimulator was ON or
OFF across all crossover phases. This noted,
previous crossover studies of FI (accepting
limitations in published documentation) have
successfully blinded participants. This remains a risk
for any placebo-controlled intervention where the
number needed to treat is relatively small; i.e. the
majority of patients can identify their stimulation
status by the effect it has on their symptoms. This
noted, the effect size of SNM vs. SHAM remains
uncertain (a reason for performing the study)
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3. The study does not address the long-term clinical
effectiveness, cost-effectiveness and safety of SNM
Cohort follow-up study
The primary study (double-blind crossover) will provide
a robust estimate of experimental efficacy. The cohort of
thus recruited patients, however, also provide an oppor-
tunity to study the outcome at a later time point with
patient-decisive stimulation (sub- or supra-sensory) as
would be normal for routine clinical practice. On this
basis, patients will be followed up for a further 6 months
to a total, therefore, of just over 1 year post implant (2 ×
16 + 26 = 58) and outcomes recorded between 54 and
58 weeks (± 1 week). Such data will provide the first esti-
mate of the outcome of optimised (internationally stan-
dardised) lead placement [25, 26] in adults with FI and
also do so with the scientific rigor mandated by a pro-
spective randomised study managed by a CTU (even if
the intervention by this stage is ‘open label’). It is ac-
knowledged that patients will only have actually had
36 weeks of stimulation (continuous or discontinuous
depending on crossover sequence). However, published
data indicate that outcomes at 6 months are almost
identical to those at later time-points (accepting data
censorship in some cohort studies).
Trial registration
The trial is registered on a publically accessible registry:
ISRCTN98760715 (Registered on 25 September 2017);
http://www.isrctn.com/ISRCTN98760715.
Trial status
The trial commenced recruitment in October 2017 and
will take 18 months to recruit 90 patients. Recruitment
milestones will be closely monitored.
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Additional file 1: Standard Protocol Items: Recommendations for
Interventional Trials (SPIRIT) 2013 Checklist: Recommended items to
address in a clinical trial protocol and related documents. (DOC 115 kb)
Abbreviations
AE: Adverse event; CI: Chief investigator; DMEC: Data Monitoring and Ethics
Committee; EQ-5D-5 L: EuroQol Health Outcome Measure; FI: Faecal
incontinence; FI QoL: Faecal Incontinence Quality of Life; GP: General
practitioner; HRA: Health Research Authority;
MEG: Magnetoencephalography; MRI: Magnetic resonance imaging;
NICE: The National Institute for Clinical Excellence; OAB Q: Assessment of
OverActive Bladder Symptoms; PCTU: Pragmatic Clinical Trials Unit;
QoL: Quality of life; R&D: Research & Development; RCT: Randomised
controlled trial; REC: Research Ethics Committee; SAE: Serious adverse event;
SF-ICQ-B: International Consultation on Incontinence Bowel Questionnaire;
SNM: Sacral neuromodulation; SOP: Standard operating procedure; TMG: Trial
Management Group; TSAR: Transient Anal Sphincter Relaxations; TSC: Trial
Steering Committee
Acknowledgements
The trial sponsor is Queen Mary University of London. Contact: Dr. Sally
Burtles, Director of Research Development, Joint Research Management
Office, 5 Walden Street, London E1 2EF. Phone: 020 7882 7260. Email:
sponsorsrep@bartshealth.nhs.uk. The sponsor and funders have no role in
study design; collection, management, analysis and interpretation of data;
writing of the report; and the decision to submit the report for publication,
including no ultimate authority over any of these activities.
Funding
This project is funded by the Efficacy and Mechanism Evaluation (EME)
Programme, an MRC and NIHR partnership: 14/144/08: £837,267.00. Further
funding (up to £160,540) has been provided by Medtronic Inc. for
mechanistic study consumables and staffing for open-label cohort follow-up.
Availability of data and materials
No supporting data are yet available as the trial is still in recruitment. Copies
of trial documents are available from PV, Clinical Research Fellow.
Authors’ contributions
CHK is the principal investigator and grant holder. CHK, TCD, AVE, PLF, SH,
RLH, JFJ, CN, PRO and SMS and are responsible for the conception and
design of the study. PV drafted this paper. CHK, EM, NS, TCD, AVE, PLF, SH,
RLH, JFJ, CN, PRO and SMS critically revised the paper for important
intellectual content and all authors read and approved the final manuscript.
Authors’ information
Eleanor McAlees is Senior Research Nurse at National Bowel Research Centre,
Blizard Institute, Barts and the London School of Medicine and Dentistry,
Queen Mary University of London, UK.
Paul F Vollebregt is Clinical Research Fellow at National Bowel Research
Centre, Blizard Institute, Barts and the London School of Medicine and
Dentistry, Queen Mary University of London, UK.
Natasha Stevens is Senior Research Programme Manager at National Bowel
Research Centre, Blizard Institute, Barts and the London School of Medicine
and Dentistry, Queen Mary University of London, UK.
Tom C Dudding is Consultant Colorectal Surgeon at University Hospital
Southampton NHS Foundation Trust, Southampton, UK.
Anton V Emmanuel is Consultant Gastroenterologist at University College
Hospital London and Academic Neurogastroenterologist at University
College London, London, UK.
Paul L Furlong is Professor of Clinical Neuroimaging and Director of Aston
Brain Centre, Aston University, Birmingham, UK.
Shaheen Hamdy is Professor of Neurogastroenterology and Consultant
Gastroenterologist at University of Manchester / Salford Royal Hospital,
Manchester and Salford, UK.
Richard L Hooper is Reader in Medical Statistics at Pragmatic Clinical Trials
Unit, Centre for Primary Care and Public Health, Queen Mary University of
London, UK.
James FX Jones is Professor of Anatomy at University College Dublin School
of Medicine, Dublin, Ireland.
Christine Norton is Professor of Clinical Nursing Research, King’s College
London, UK.
P Ronan O’Connell is Professor of Surgery and Consultant Colorectal Surgeon
at University College Dublin School of Medicine / St. Vincent’s University
Hospital, Dublin, Ireland.
S Mark Scott is Senior Clinical Scientist and Director of the GI Physiology Unit
(Colorectal Service) at Queen Mary University of London / Barts Health NHS
Trust, London, UK.
Charles H Knowles is Professor of Surgery and Honorary Consultant
Colorectal Surgeon at Queen Mary University of London / Barts Health NHS
Trust, London, UK.
Ethics approval and consent to participate
The research is performed in accordance with the Declaration of Helsinki.
Informed consent will be obtained from all participants in the study. The
chief investigator (CI: CK) has obtained approval for the trial from a
recognised committee of the UK HRA National Research Ethics Service,
London City and East REC (Reference 17/LO/1060, IRAS 187783) on 13
September 2017.
McAlees et al. Trials  (2018) 19:336 Page 17 of 19
Competing interests
EM, PFV, NS, AVE, PLF, RLH, JFJ and CN have no conflict of interest. TCD has
received financial remuneration from Medtronic Inc. and Axonics
Neuromodulation Technologies as honoraria and participation on expert
advisory committees. SH has received funding from the University of
Manchester, Enteric HTC, and the Small Business Research Initiative (SBRI)
fund to develop a diagnostic device to assess faecal incontinence. PRO has
received financial remuneration from Medtronic Inc. as speaker fees and
financial support for contract research, and has also received financial
remuneration from Ethicon Endosurgery as speaker and consultation fees,
and consultation fees from MSD. SMS has received honoraria for teaching
from MMS/Laborie. CHK has received financial remuneration from Medtronic
Inc. as speaker fees and for expert advisory committees.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1National Bowel Research Centre, Blizard Institute, Barts and the London School
of Medicine and Dentistry, Queen Mary University of London, London, UK.
2University Hospital Southampton NHS Foundation Trust, Southampton, UK.
3University College Hospital, London, UK. 4Aston Brain Centre, Aston University,
Birmingham, UK. 5University of Manchester and Salford Royal Hospital,
Manchester and Salford, UK. 6Pragmatic Clinical Trials Unit, Centre for Primary
Care and Public Health, Queen Mary University of London, London, UK.
7University College Dublin School of Medicine, Dublin, Ireland. 8King’s College,
London, UK. 9National Bowel Research Centre, 1st Floor Abernethy Building, 2
Newark St, London E1 2A, UK.
Received: 6 February 2018 Accepted: 16 May 2018
References
1. Norton C, Whitehead W, Bliss D, Harari D, Lang J. Conservative and
pharmacological management of fecal incontinence in adults. In:
Incontinence. Plybridge; 2009.
2. Whitehead WE, Borrud L, Goode PS, Meikle S, Mueller ER, Tuteja A, Weidner
A, Weinstein M, Ye W, Network PFD. Fecal incontinence in US adults:
epidemiology and risk factors. Gastroenterology. 2009;137:512–517. e512.
3. Leigh R, Turnberg L. Faecal incontinence: the unvoiced symptom. Lancet.
1982;319:1349–51.
4. Norton C, Thomas L, Hill J. NICE guidelines: management of faecal
incontinence in adults: summary of NICE guidance. BMJ. 2007;334:1370.
5. Norton C, Cody JD. Biofeedback and/or sphincter exercises for the treatment of
faecal incontinence in adults. Cochrane Database Syst Rev. 2012;(7):CD002111.
https://doi.org/10.1002/14651858.CD002111.pub3.
6. Thin NN, Horrocks EJ, Hotouras A, Palit S, Thaha MA, Chan CL, Matzel KE,
Knowles CH. Systematic review of the clinical effectiveness of
neuromodulation in the treatment of faecal incontinence. Br J Surg. 2013;
100:1430–47.
7. Dudding TC, Meng Lee E, Faiz O, Pares D, Vaizey CJ, McGuire A, Kamm MA.
Economic evaluation of sacral nerve stimulation for faecal incontinence. Br J
Surg. 2008;95:1155–63.
8. Hull T, Giese C, Wexner SD, Mellgren A, Devroede G, Madoff RD, Stromberg
K, Coller JA. Long-term durability of sacral nerve stimulation therapy for
chronic fecal incontinence. Dis Colon Rectum. 2013;56:234.
9. Wexner SD, Coller JA, Devroede G, Hull T, McCallum R, Chan M, Ayscue JM,
Shobeiri AS, Margolin D, England M, et al. Sacral nerve stimulation for fecal
incontinence: results of a 120-patient prospective multicenter study. Ann
Surg. 2010;251:441–9.
10. Altomare DF, Giuratrabocchetta S, Knowles CH, Munoz Duyos A, Robert-Yap
J, Matzel KE. Long-term outcomes of sacral nerve stimulation for faecal
incontinence. Br J Surg. 2015;102:407–15.
11. Maeda Y, Lundby L, Buntzen S, Laurberg S. Outcome of sacral nerve
stimulation for fecal incontinence at 5 years. Ann Surg. 2014;259:1126–31.
12. Thaha MA, Abukar AA, Thin NN, Ramsanahie A, Knowles CH. Sacral nerve
stimulation for faecal incontinence and constipation in adults. Cochrane
Database Syst Rev. 2015:Cd004464. http://www.cochrane.org/CD004464/
INCONT_sacral-nerve-stimulation-treating-faecal-incontinence-and-
constipation-adults.
13. Vaizey CJ, Kamm MA, Roy AJ, Nicholls RJ. Double-blind crossover study
of sacral nerve stimulation for fecal incontinence. Dis Colon Rectum.
2000;43:298–302.
14. Sorensen MT. Sacral nerve stimulation increases rectal sensitivity in patients
with faecal incontinence: results of a randomised double-blinded crossover
study. In: Proceedings of the Joint Meeting of the International Continence
Society (ICS) and the International Urogynecological Association 2010,
Abstract 437; Toronto, Canada.
15. Leroi AM, Parc Y, Lehur PA, Mion F, Barth X, Rullier E, Bresler L, Portier G,
Michot F. Efficacy of sacral nerve stimulation for fecal incontinence: results
of a multicenter double-blind crossover study. Ann Surg. 2005;242:662–9.
16. Kahlke V, Topic H, Peleikis HG, Jongen J. Sacral nerve modulation for fecal
incontinence: results of a prospective single-center randomized crossover
study. Dis Colon Rectum. 2015;58:235–40.
17. Tjandra JJ, Chan MK, Yeh CH, Murray-Green C. Sacral nerve stimulation is
more effective than optimal medical therapy for severe fecal incontinence:
a randomized, controlled study. Dis Colon Rectum. 2008;51:494–502.
18. Thin NN, Taylor SJ, Bremner SA, Emmanuel AV, Hounsome N, Williams
NS, Knowles CH. Randomized clinical trial of sacral versus percutaneous
tibial nerve stimulation in patients with faecal incontinence. Br J Surg.
2015;102:349–58.
19. Matzel KE, Schmidt RA, Tanagho EA. Neuroanatomy of the striated muscular
anal continence mechanism. Implications for the use of neurostimulation.
Dis Colon Rectum. 1990;33:666–73.
20. Dudding TC, Pares D, Vaizey CJ, Kamm MA. Predictive factors for successful
sacral nerve stimulation in the treatment of faecal incontinence: a 10-year
cohort analysis. Color Dis. 2008;10:249–56.
21. Lunniss PJ, Gladman MA, Hetzer FH, Williams NS, Scott SM. Risk factors in
acquired faecal incontinence. J R Soc Med. 2004;97:111–6.
22. Altomare DF, Giannini I, Giuratrabocchetta S, Digennaro R. The effects of
sacral nerve stimulation on continence are temporarily maintained after
turning the stimulator off. Color Dis. 2013;15:e741–8.
23. La TH, Groen J, Scheepe JR, Blok BF. Intermittent sacral neuromodulation for
idiopathic urgency urinary incontinence in women. Neurourol Urodyn.
2017;36:385–9.
24. Price DM, Noblett K. Prospective randomized crossover trial comparing
continuous and cyclic stimulation in InterStim therapy. Female Pelvic Med
Reconstr Surg. 2015;21:355–8.
25. Williams ER, Siegel SW. Procedural techniques in sacral nerve modulation.
Int Urogynecol J. 2010;21(Suppl 2):S453–60.
26. Matzel KE, Chartier-Kastler E, Knowles CH, Lehur PA, Munoz-Duyos A, Ratto
C, Rydningen MB, Sorensen M, van Kerrebroeck P, de Wachter S. Sacral
neuromodulation: standardized electrode placement technique.
Neuromodulation. 2017;20:816–24.
27. Duelund-Jakobsen J, Buntzen S, Lundby L, Laurberg S. Sacral nerve stimulation
at subsensory threshold does not compromise treatment efficacy: results from
a randomized, blinded crossover study. Ann Surg. 2013;257:219–23.
28. Carrington EV, Brokjaer A, Craven H, Zarate N, Horrocks EJ, Palit S, Jackson W,
Duthie GS, Knowles CH, Lunniss PJ, Scott SM. Traditional measures of normal
anal sphincter function using high-resolution anorectal manometry (HRAM) in
115 healthy volunteers. Neurogastroenterol Motil. 2014;26:625–35.
29. Vaizey CJ. Faecal incontinence: standardizing outcome measures. Color Dis.
2014;16:156–8.
30. Graf W, Mellgren A, Matzel KE, Hull T, Johansson C, Bernstein M. Efficacy of
dextranomer in stabilised hyaluronic acid for treatment of faecal incontinence:
a randomised, sham-controlled trial. Lancet. 2011;377:997–1003.
31. Vaizey CJ, Carapeti E, Cahill JA, Kamm MA. Prospective comparison of faecal
incontinence grading systems. Gut. 1999;44:77–80.
32. Rockwood TH, Church JM, Fleshman JW, Kane RL, Mavrantonis C, Thorson
AG, Wexner SD, Bliss D, Lowry AC. Fecal Incontinence Quality of Life Scale:
quality of life instrument for patients with fecal incontinence. Dis Colon
Rectum. 2000;43:9–16. discussion 16-17
33. Cotterill N, Norton C, Avery KN, Abrams P, Donovan JL. Psychometric
evaluation of a new patient-completed questionnaire for evaluating anal
incontinence symptoms and impact on quality of life: the ICIQ-B. Dis Colon
Rectum. 2011;54:1235–50.
34. Knowles CH, Horrocks EJ, Bremner SA, Stevens N, Norton C, O'Connell PR,
Eldridge S. Percutaneous tibial nerve stimulation versus sham electrical
stimulation for the treatment of faecal incontinence in adults (CONFIDeNT):
a double-blind, multicentre, pragmatic, parallel-group, randomised
controlled trial. Lancet. 2015;386:1640–8.
McAlees et al. Trials  (2018) 19:336 Page 18 of 19
35. Hillebrand A, Singh KD, Holliday IE, Furlong PL, Barnes GR. A new approach
to neuroimaging with magnetoencephalography. Hum Brain Mapp. 2005;
25:199–211.
36. Koch SM, van Gemert WG, Baeten CG. Determination of therapeutic
threshold in sacral nerve modulation for faecal incontinence. Br J Surg.
2005;92:83–7.
37. Dinning PG, Hunt LM, Arkwright JW, Patton V, Szczesniak MM, Wiklendt L,
Davidson JB, Lubowski DZ, Cook IJ. Pancolonic motor response to
subsensory and suprasensory sacral nerve stimulation in patients with slow-
transit constipation. Br J Surg. 2012;99:1002–10.
38. Fassov JL, Lundby L, Laurberg S, Buntzen S, Krogh K. A randomized,
controlled, crossover study of sacral nerve stimulation for irritable bowel
syndrome. Ann Surg. 2014;260:31–6.
McAlees et al. Trials  (2018) 19:336 Page 19 of 19
